Elahere

Active Ingredient(s): Mirvetuximab Soravtansine-gynx
FDA Approved: * November 14, 2022
Pharm Company: * IMMUNOGEN INC
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Elahere 100 mg/20ml Intravenous Injection, Solution
NDC: 72903-853
Labeler:
Immunogen, Inc.